Novo Nordisk's Amycretin - Evergreening The Franchise Part II At their 2024 capital markets day Novo Nordisk announced results for their second follow up to semaglutide Amycretin
Textor, J., van der Zander, B., Gilthorpe, M
The biggest challenge is patience and consistency
In contrast to most modalities that have their effect globally with some immune system level change and/or change in more global control of hormonal function, BPC 157 is thought to work locally as a dressing in the injury itself through a number of different potential mechanisms: inducing angiogenesis (new blood vessel formation), reducing inflammation, and inducing development of new tissue
Within approved trials, preparation is carried out solely by trained pharmacy or clinical staff under strictly controlled aseptic conditions, using validated protocols specific to each trial formulation